BioShares Biotech Clinical Trials Fund, Up 5%, Is Today’s Top Performing ETF

Share This Article
January 31, 2017 5:42pm NASDAQ:BBC

biotech-white-pills

The BioShares Biotechnology Clinical Trials Fund (BBC) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a +5.03% one-day return and outperforming the wider markets by a total of 5.04 percentage points.


Behind The Gains

BBC closed today at $19.84 per share, up $0.95 (+5.03%). Putting this move in context, the S&P 500 index — largely considered the most popular and useful benchmark for equity performance — closed down $-0.02 (-0.01%) on the day.

BBC’s trading volume today was a total of 12,241 shares, which was a decrease of 4% versus its average daily trading volume of 12,737. Rising trading volume generally an indicator of increased demand for a particular security, and is typically associated with a specific news event or trend that draws investors into or out of specific asset classes, or sectors or subsectors within those classes.

Including any dividends as well as today’s gains, BBC has now returned a total of 7.77% year-to-date, versus a 1.79% gain in the S&P 500 during the same timeframe.

A Look Under The Hood

BioShares Biotechnology Clinical Trials Fund is a Equity-focused product issued by BioShares. Its expense ratio of 0.85% makes it the #34 cheapest ETF among 35 total funds in the Health & Biotech ETFs category.

BBC currently boasts $18.89M in assets under management (AUM), placing it #28 of 35 ETFs in its category, and #1325 of 1922 total ETFs in the U.S. exchange traded universe.

The investment objective of the BioShares Biotechnology Clinical Trials ETF seeks investment results that correspond to the price and yield performance of the BioShares Biotechnology Clinical Trials Index. The clinical trials index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development.

BBC SMART Grade

BBC currently has an ETF Daily News SMART Grade of C (Neutral), and is ranked #28 of 36 funds in the Health & Biotech ETFs category.

For more information about this ETF, including full ratings, news, data, and more, please visit BBC’s ticker page.

Want Important ETF Info Delivered Straight To Your Inbox?

The ETF Daily News Free Daily Newsletter will brief you on top news and analysis, as well as top performing ETFs, each and every day. Get it free »


Read Next


Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories